Pharmacyclics (PCYC) Tops Q4 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Pharmacyclics (PCYC) Tops Q4 EPS by 20c
February 19, 2015 9:04 AM EST
RBC Capital maintained a Sector Perform rating on Pharmacyclics (NASDAQ: PCYC) and raised its price target to $145.00 (from $130.00). Comments follow Q4 results. Analyst Michael J. Yee thinks bulls are in control of the stock.
"We predict stock likely to keep trending up... More
February 19, 2015 6:59 AM EST
Nomura Securities upgraded Pharmacyclics (NASDAQ: PCYC) from Neutral to Buy with a price target of $196.00 (from $195.00), saying the RESONATE-2 data is key to upside in 2015
Analyst M. Ian Somaiya commented, "Pharmacyclics management reaffirmed their 2015 US sales guidance of $1bn and more importantly confirmed results of... More
February 19, 2015 6:56 AM EST
(Updated - February 19, 2015 8:59 AM EST)
Roth Capital cuts Pharmacyclics (Nasdaq: PCYC) from Buy to Neutral and moves its price target from $189 to $187 following FY14 results reported on Wednesday night.
After markets close, Pharmacyclics posted Q4 EPS of $0.96 on revs of $290... More
February 19, 2015 6:55 AM EST
JPMorgan downgraded Pharmacyclics (NASDAQ: PCYC) from Overweight to Neutral with a price target of $173.00 (from $152.00).
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $170.21 yesterday.
...
More
